CL2018002034A1 - Proteínas de unión a antígeno que se unen a pd-l1. - Google Patents

Proteínas de unión a antígeno que se unen a pd-l1.

Info

Publication number
CL2018002034A1
CL2018002034A1 CL2018002034A CL2018002034A CL2018002034A1 CL 2018002034 A1 CL2018002034 A1 CL 2018002034A1 CL 2018002034 A CL2018002034 A CL 2018002034A CL 2018002034 A CL2018002034 A CL 2018002034A CL 2018002034 A1 CL2018002034 A1 CL 2018002034A1
Authority
CL
Chile
Prior art keywords
bind
antigen binding
binding proteins
disclosed
antibodies
Prior art date
Application number
CL2018002034A
Other languages
English (en)
Spanish (es)
Inventor
Heyue Zhou
Original Assignee
Sorrento Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sorrento Therapeutics Inc filed Critical Sorrento Therapeutics Inc
Publication of CL2018002034A1 publication Critical patent/CL2018002034A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
CL2018002034A 2016-01-29 2018-07-27 Proteínas de unión a antígeno que se unen a pd-l1. CL2018002034A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662288912P 2016-01-29 2016-01-29

Publications (1)

Publication Number Publication Date
CL2018002034A1 true CL2018002034A1 (es) 2019-03-15

Family

ID=59386438

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2018002034A CL2018002034A1 (es) 2016-01-29 2018-07-27 Proteínas de unión a antígeno que se unen a pd-l1.

Country Status (17)

Country Link
US (4) US10118963B2 (enExample)
EP (1) EP3408400B1 (enExample)
JP (3) JP6883590B2 (enExample)
KR (2) KR102927822B1 (enExample)
CN (2) CN116333124A (enExample)
AU (1) AU2017212717B2 (enExample)
BR (1) BR112018015480A2 (enExample)
CA (1) CA3013051A1 (enExample)
CL (1) CL2018002034A1 (enExample)
EA (1) EA037855B1 (enExample)
ES (1) ES2986360T3 (enExample)
IL (1) IL260846B2 (enExample)
MX (2) MX2018009228A (enExample)
PH (1) PH12018501611A1 (enExample)
SG (1) SG11201806496SA (enExample)
TW (1) TWI760323B (enExample)
WO (1) WO2017132562A1 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9175082B2 (en) * 2012-05-31 2015-11-03 Sorrento Therapeutics, Inc. Antigen binding proteins that bind PD-L1
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
US9139653B1 (en) 2015-04-30 2015-09-22 Kymab Limited Anti-human OX40L antibodies and methods of treatment
ES2986360T3 (es) * 2016-01-29 2024-11-11 Yuhan Corp Proteínas de unión a antígeno que se unen a PD-L1
KR102379464B1 (ko) 2016-06-20 2022-03-29 키맵 리미티드 항-pd-l1 항체
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
WO2018083248A1 (en) 2016-11-03 2018-05-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
WO2019180201A2 (en) * 2018-03-22 2019-09-26 Keires Ag Antagonistic antigen binding proteins
CA3095498A1 (en) 2018-04-09 2019-10-17 Origincell Therapeutics Co., Ltd. Anti-pd-l1 antibody and use thereof
WO2019227490A1 (en) * 2018-06-01 2019-12-05 Tayu Huaxia Biotech Medical Group Co., Ltd. Compositions and methods for imaging
JP2021525806A (ja) * 2018-06-01 2021-09-27 タユー ファシャ バイオテック メディカル グループ カンパニー， リミテッド 疾患または状態を処置するための組成物およびそれらの使用
WO2020038379A1 (en) * 2018-08-20 2020-02-27 1Globe Biomedical Co., Ltd. Novel cancer immunotherapy antibody compositions
WO2020123543A2 (en) * 2018-12-11 2020-06-18 Sanford Burnham Prebys Medical Discovery Institute Models and methods useful for the treatment of serrated colorectal cancer
CN113795511B (zh) 2019-01-23 2024-07-23 大有华夏生物医药集团有限公司 抗pd-l1双抗体及其用途
CA3136453A1 (en) 2019-04-18 2020-10-22 Qlsf Biotherapeutics Inc. Humanized anti-pd-l1 antibodies
US12404333B2 (en) 2019-08-29 2025-09-02 Remegen Co., Ltd. Anti PD-L1 antibody and use thereof
CA3183673A1 (en) * 2020-06-26 2021-12-30 Robert Allen Oncolytic herpes simplex viruses (hsv) expressing immunomodulatory fusion proteins
US20230338574A1 (en) 2020-09-02 2023-10-26 Mayo Foundation For Medical Education And Research Antibody-nanoparticle complexes and methods for making and using the same
US20230416369A1 (en) 2020-11-16 2023-12-28 Immuneoncia Therapeutics, Inc. Biomarker for predicting therapeutic responsiveness to cancer immunotherapeutic agent and use thereof
WO2022235127A1 (ko) 2021-05-07 2022-11-10 주식회사 이뮨온시아 Cd47 및 pd-l1에 특이적으로 결합하는 이중특이적 항체
AU2022290563A1 (en) 2021-06-09 2024-01-25 Sofusa Holdings Llc Method of treating cancer by administration of an anti-pd-1 or anti-pd-l1 therapeutic agent via a lymphatic microneedle delivery device
MX2024001877A (es) 2021-08-10 2024-02-28 Kymab Ltd Tratamiento de dermatitis atopica.
EP4590328A2 (en) * 2022-09-19 2025-07-30 Sonoma Biotherapeutics, Inc. Citrullinated antigen-specific chimeric antigen receptors for targeting regulatory t cells to treat hidradenitis suppurativa
US20240294651A1 (en) 2023-01-30 2024-09-05 Kymab Limited Antibodies
WO2025183487A1 (en) * 2024-02-29 2025-09-04 Yuhan Corporation Anti-tigit/anti-pd-l1 bispecific antibody and use thereof
IL323020A (en) 2024-04-13 2026-03-01 Immuneoncia Therapeutics Inc Neoadjuvant immunotherapy with pd-l1 inhibitor in treating cancer
KR102961530B1 (ko) 2024-04-13 2026-05-08 주식회사 이뮨온시아 암 치료를 위한 pd-l1 저해제를 이용한 신보조요법

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3817827A (en) 1972-03-30 1974-06-18 Scott Paper Co Soft absorbent fibrous webs containing elastomeric bonding material and formed by creping and embossing
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4002531A (en) 1976-01-22 1977-01-11 Pierce Chemical Company Modifying enzymes with polyethylene glycol and product produced thereby
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US6010902A (en) 1988-04-04 2000-01-04 Bristol-Meyers Squibb Company Antibody heteroconjugates and bispecific antibodies for use in regulation of lymphocyte activity
US5766897A (en) 1990-06-21 1998-06-16 Incyte Pharmaceuticals, Inc. Cysteine-pegylated proteins
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
JP3051145B2 (ja) 1990-08-28 2000-06-12 住友製薬株式会社 新規なポリエチレングリコール誘導体修飾ペプチド
US5582996A (en) 1990-12-04 1996-12-10 The Wistar Institute Of Anatomy & Biology Bifunctional antibodies and method of preparing same
DE4118120A1 (de) 1991-06-03 1992-12-10 Behringwerke Ag Tetravalente bispezifische rezeptoren, ihre herstellung und verwendung
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US5281698A (en) 1991-07-23 1994-01-25 Cetus Oncology Corporation Preparation of an activated polymer ester for protein conjugation
EP0604580A1 (en) 1991-09-19 1994-07-06 Genentech, Inc. EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab') 2? ANTIBODIES
JPH05244982A (ja) 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化ｂ−ｂ１０
DE69332377T2 (de) 1992-07-13 2003-07-03 Bionebraska, Inc. Verfahren zur modifizierung rekombinanter polypeptide
US5382657A (en) 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
PT672141E (pt) 1992-10-23 2003-09-30 Immunex Corp Metodos de preparacao de proteinas oligomericas soluveis
US5446090A (en) 1993-11-12 1995-08-29 Shearwater Polymers, Inc. Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
JP2002522063A (ja) 1998-08-17 2002-07-23 アブジェニックス インコーポレイテッド 増加した血清半減期を有する改変された分子の生成
GB9928787D0 (en) 1999-12-03 2000-02-02 Medical Res Council Direct screening method
US6938003B2 (en) 2000-06-30 2005-08-30 Mahesh Harpale Method and apparatus for a credibility reporting system to augment an online exchange
US7052686B2 (en) 2000-09-29 2006-05-30 Schering Corporation Pegylated interleukin-10
GB0025144D0 (en) 2000-10-13 2000-11-29 Medical Res Council Concatenated nucleic acid sequences
US20040202995A1 (en) 2003-04-09 2004-10-14 Domantis Nucleic acids, proteins, and screening methods
US7902338B2 (en) * 2003-07-31 2011-03-08 Immunomedics, Inc. Anti-CD19 antibodies
EP2162149B1 (en) 2007-06-01 2013-11-06 The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. Vaccine for the prevention of breast cancer relapse
US8877688B2 (en) * 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
US9175082B2 (en) * 2012-05-31 2015-11-03 Sorrento Therapeutics, Inc. Antigen binding proteins that bind PD-L1
BR112015007672A2 (pt) 2012-10-04 2017-08-08 Dana Farber Cancer Inst Inc anticorpos anti-pd-l1 monoclonais humanos e métodos de uso
AR093984A1 (es) * 2012-12-21 2015-07-01 Merck Sharp & Dohme Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano
CA3175360C (en) * 2013-05-31 2024-05-28 Sorrento Therapeutics, Inc. Antigen binding proteins that bind pd-1
JP6759104B2 (ja) * 2014-04-04 2020-09-23 メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ 精密分子質量を用いた免疫グロブリンのアイソタイピング
CN105238762A (zh) * 2015-10-26 2016-01-13 无锡傲锐东源生物科技有限公司 抗pd-1蛋白单克隆抗体杂交瘤细胞及其产生的抗pd-1单克隆抗体和应用
ES2986360T3 (es) * 2016-01-29 2024-11-11 Yuhan Corp Proteínas de unión a antígeno que se unen a PD-L1

Also Published As

Publication number Publication date
EA201891709A1 (ru) 2019-01-31
US20240190959A1 (en) 2024-06-13
US10118963B2 (en) 2018-11-06
SG11201806496SA (en) 2018-08-30
CN109715821A (zh) 2019-05-03
MX2022011659A (es) 2022-10-13
WO2017132562A1 (en) 2017-08-03
TW201736400A (zh) 2017-10-16
CN109715821B (zh) 2022-09-06
EA037855B1 (ru) 2021-05-27
PH12018501611A1 (en) 2019-04-08
KR102927822B1 (ko) 2026-02-13
NZ745357A (en) 2025-08-29
US20210147539A1 (en) 2021-05-20
AU2017212717A1 (en) 2018-09-06
ES2986360T3 (es) 2024-11-11
KR20260041830A (ko) 2026-03-27
EP3408400A1 (en) 2018-12-05
JP2019507183A (ja) 2019-03-14
AU2017212717B2 (en) 2023-11-16
CN116333124A (zh) 2023-06-27
TWI760323B (zh) 2022-04-11
WO2017132562A8 (en) 2017-09-08
US10919964B2 (en) 2021-02-16
US20170218066A1 (en) 2017-08-03
IL260846A (enExample) 2018-09-20
KR20190026642A (ko) 2019-03-13
JP2021102633A (ja) 2021-07-15
US20190092861A1 (en) 2019-03-28
US11919952B2 (en) 2024-03-05
JP7140867B2 (ja) 2022-09-21
IL260846B2 (en) 2023-02-01
EP3408400A4 (en) 2019-11-27
JP2022095910A (ja) 2022-06-28
BR112018015480A2 (pt) 2019-05-21
IL260846B (en) 2022-10-01
CA3013051A1 (en) 2017-08-03
MX2018009228A (es) 2019-07-08
EP3408400B1 (en) 2024-06-26
EP3408400C0 (en) 2024-06-26
JP6883590B2 (ja) 2021-06-09

Similar Documents

Publication Publication Date Title
MX2018009228A (es) Proteínas de unión a antigeno que se unen a pd-l1.
IL280673A (en) Proteins binding nkg2d, cd16 and a tumor-associated antigen
CL2018003378A1 (es) Proteínas de unión biespecíficas que se unen a una proteína inmunomoduladora y a un antígeno.
CR20150575A (es) Anticuerpos humanos pac1
SI3638698T1 (sl) Protitelesa proti-TMPRSS2 in delci, ki vežejo antigen
CL2023001064A1 (es) Proteína de unión al antígeno anti-steap1
CO2018005436A2 (es) Anticuerpos y fragmentos de anticuerpo para la conjugación sitio-específica
IL280618A (en) Proteins binding nkg2d, cd16 and a tumor-associated antigen
MX391028B (es) Anticuerpos que se unen a cd39 y sus usos
EA202190542A1 (ru) Сконструированные биспецифические белки
BR112018014760A2 (pt) anticorpos anti-ror1, anticorpos biespecíficos para ror1 x cd3 e métodos de uso dos mesmos
IL270803A (en) A protein binding nkg2d, cd16 and a tumor-associated antigen
CR20170383A (es) Anticuerpos anti-cd3, anticuerpos anti-cd-123 y anticuerpos biespecíficos que se unen específicamente a cd3 y/o cd123
IL269074A (en) Anti-tigit antigen-binding proteins and methods of use thereof
PL3461261T3 (pl) Białka wiążące jednołańcuchowy fragment zmienny CD3
IL285668A (en) Bispecific fusion protein using orthopoxvirus major histocompatibility complex (mhc) class l-like protein (omcp) and tumor-specific binding partner
CR20140585A (es) Proteinas de union a antigeno st2
SI3328889T1 (sl) Konstrukti bispecifičnih protiteles, ki vežejo DLL3 in CD3
MX2016012578A (es) Anticuerpos biespecificos que se unen a cd38 y cd3.
EA201691321A1 (ru) Антитела и способы их применения
UY36731A (es) Proteinas de unión contra vegf, pdgf, y/o sus receptores
IL289100A (en) Egfr antigen binding fragments and compositions comprising same
CR20170020A (es) Variantes de proteínas de unión al factor h y métodos de uso de estas
CO2019003759A2 (es) Anticuerpos que se unen a la proteína de envoltura del virus zika y usos de los mismos
EA201892096A1 (ru) Нейтрализующие моноклональные антитела к il-25 и их применение